Terapias Basadas en Citoquinas
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (7)
2022
-
Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
Cancer research, Vol. 82, Núm. 23, pp. 4373-4385
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
2021
-
Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 41, Núm. 9, pp. E440-E452
-
High prevalence of insulin resistance in asymptomatic patients with acute intermittent porphyria and liver-targeted insulin as a novel therapeutic approach
Biomedicines, Vol. 9, Núm. 3, pp. 1-18
2019
-
Messenger RNA therapy for rare genetic metabolic diseases
Gut, Vol. 68, Núm. 7, pp. 1323-1330
2018
-
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909